RUNX1 and breast cancer: Our research study has introduced novel insights into this landscape by demonstrating that EI, a compound derived from traditional Chinese medicine, exerts its action by inhibiting AR/RUNX1 signaling, thereby reversing paclitaxel resistance in BC cells.